Phenominer Database Results (20 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
SS/NEisSlc systolic blood pressure controlled cilazapril content drinking water (2.5 ug/ml) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. arterial blood pressure trait not specified 547 days 10 136.0 mmHg 3.0 9.49 vascular indwelling catheter method femoral artery 0.0 0 106788 2339
SS/NEisSlc serum NAG activity level controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood enzyme amount not specified 547 days 10 17.0 uU/ml 0.9 2.85 blood NAG activity assay 0.0 0 blood NAG activity assay (MMO:0000723) serum NAG activity level (CMO:0003487) 107427 2339
SS/NEisSlc neuron count controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. hippocampus neuron quantity not specified 547 days 10 1466.0 cells/mm2 42.0 132.82 ex vivo light microscopy with histochemistry 0.0 0 107466 2339
SS/NEisSlc water drink intake rate controlled cilazapril content drinking water (2.5 ug/ml) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. drinking behavior trait not specified 547 days 10 35.1 ml/d 3.2 10.12 drink intake measuring method 0.0 0 106785 2339
SS/NEisSlc water drink intake rate controlled cilazapril content drinking water (12.5 ug/ml) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. drinking behavior trait not specified 547 days 10 40.5 ml/d 5.4 17.08 drink intake measuring method 0.0 0 106786 2339
SS/NEisSlc systolic blood pressure controlled cilazapril content drinking water (12.5 ug/ml) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. arterial blood pressure trait not specified 547 days 10 122.0 mmHg 4.0 12.65 vascular indwelling catheter method femoral artery 0.0 0 106789 2339
SS/NEisSlc urine total protein excretion rate controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. total urine protein amount not specified 547 days 10 204.8 mg/d 16.0 50.6 urine total protein analysis 0.0 0 107438 2339
SS/NEisSlc time to first movement outside a discrete space in an experimental apparatus controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. locomotor behavior trait not specified 63 days-236 days 10 397.0 s 3.0 9.49 passive avoidance test using a two-way shuttle box apparatus 0.0 electric foot shock 18 days passive avoidance test using a two-way shuttle box apparatus (MMO:0000725) 107470 2339
SS/NEisSlc serum NAG activity level controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood enzyme amount not specified 547 days 10 19.1 uU/ml 1.7 5.38 blood NAG activity assay 0.0 0 blood NAG activity assay (MMO:0000723) serum NAG activity level (CMO:0003487) 107426 2339
SS/NEisSlc heart weight to body weight ratio controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. heart mass not specified 547 days 10 2.8 g/kg 0.1 0.32 post excision weight measurement 0.0 0 106794 2339
SS/NEisSlc timed urine volume to body weight ratio controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. urine output not specified 547 days 10 0.02 ul/min/g 0.0 0.01 urine volume measurement method 0.0 0 107431 2339
SS/NEisSlc creatinine clearance to body weight ratio controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. glomerular filtration trait not specified 547 days 10 0.42 ml/min/100g 0.02 0.07 plasma creatinine analysis 0.0 0 107442 2339
SS/NEisSlc plasma creatinine level controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood creatinine amount not specified 547 days 10 0.51 mg/dl 0.02 0.06 plasma creatinine analysis 0.0 0 107422 2339
SS/NEisSlc plasma creatinine level controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. blood creatinine amount not specified 547 days 10 0.49 mg/dl 0.0 0.0 plasma creatinine analysis 0.0 0 107423 2339
SS/NEisSlc urine total protein excretion rate controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. total urine protein amount not specified 547 days 10 182.9 mg/d 12.1 38.26 urine total protein analysis 0.0 0 107439 2339
SS/NEisSlc neuron count controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. hippocampus neuron quantity not specified 547 days 10 1491.0 cells/mm2 57.0 180.25 ex vivo light microscopy with histochemistry 0.0 0 107467 2339
SS/NEisSlc heart weight to body weight ratio controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. heart mass not specified 547 days 10 3.0 g/kg 0.1 0.32 post excision weight measurement 0.0 0 106793 2339
SS/NEisSlc time to first movement outside a discrete space in an experimental apparatus controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. locomotor behavior trait not specified 63 days-236 days 10 389.0 s 11.0 34.79 passive avoidance test using a two-way shuttle box apparatus 0.0 electric foot shock 18 days passive avoidance test using a two-way shuttle box apparatus (MMO:0000725) 107469 2339
SS/NEisSlc timed urine volume to body weight ratio controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. urine output not specified 547 days 10 0.02 ul/min/g 0.0 0.0 urine volume measurement method 0.0 0 107430 2339
SS/NEisSlc creatinine clearance to body weight ratio controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. glomerular filtration trait not specified 547 days 10 0.45 ml/min/100g 0.07 0.22 plasma creatinine analysis 0.0 0 107443 2339